An experimental immunotherapy given without chemotherapy kept patients with advanced squamous lung cancer alive a median of 18.5 months, compared with 10.0 months for those who received standard chemotherapy, according to updated trial data released Monday by BioNTech and its partner OncoC4.
The figures come from the first, non-pivotal stage of the PRESERVE-003 Phase 3 trial and were presented at the World Conference on Lung Cancer in Seoul. In their joint announcement, the companies said the drug, gotistobart, produced a hazard ratio of 0.56 against docetaxel, the chemotherapy that has anchored this stage of treatment for more than a decade. That figure corresponds to a 44% lower risk of death during the follow-up window, with a nominal p-value of 0.0295.
The patients involved had already run out of the two options most people rely on. Their cancer had grown despite a PD-1 or PD-L1 immunotherapy and despite platinum chemotherapy. For that group, median survival with existing treatment sits under a year.
Second Line Patients Have Had Few Real Options for Years
This is the part of lung cancer treatment that families rarely hear about until they are in it. First-line immunotherapy has changed outcomes for many people. When it stops working, the menu narrows sharply, and docetaxel remains the fallback.
Rama Balaraman, a medical oncologist at Ocala Oncology Center in Florida and a principal investigator on the trial, said survival expectations with established therapies in this setting remain less than a year and that chemotherapy has held the standard-of-care position for more than a decade despite many attempts to replace it. The companies cite a squamous lung cancer five-year relative survival rate of 15% and a median survival of 11 months in the United States, based on an analysis of registry data from 2000 through 2017.
Gotistobart works differently from the CTLA-4 drugs already on the market. Its binding to CTLA-4 is pH-sensitive, a design meant to deplete suppressive regulatory T cells inside the tumor while preserving checkpoint function in healthy tissue. That design is the reason researchers are watching side effects as closely as survival.
On that front, the new numbers were reassuring rather than remarkable. Grade 3 or higher treatment-related side effects occurred in 44.4% of patients on gotistobart and 48.8% of those on docetaxel. The companies described the safety profile as manageable and consistent with earlier reports. Tolerability has been a live question for this drug class, and earlier analyst commentary on the same trial stage flagged a high rate of immune-related adverse events and more discontinuations with gotistobart than with the comparison drug.
Inside the Numbers Presented in Seoul
The data cut-off was July 17, 2026, with a median follow-up of 25.4 months. Eighty-seven patients with metastatic squamous disease were randomized: 45 received gotistobart at 6 mg/kg after two 10 mg/kg loading doses, and 42 received docetaxel at 75 mg/m².
Earlier results from this stage had shown a survival advantage, but median survival on gotistobart had not yet been reached, and the hazard ratio at that point was 0.46. Longer follow-up allowed researchers to put a number on median survival, and the hazard ratio moved to 0.56. Findings from that earlier analysis were published in Nature Medicine and presented at the European Lung Cancer Congress in March, as well as at a North American lung cancer meeting in December.
Gotistobart has received Fast Track designation from the FDA for metastatic non-small cell lung cancer that progressed on prior anti-PD-(L)1 therapy, along with orphan drug designation in squamous lung cancer and breakthrough therapy designation from China's National Medical Products Administration.
MedicalDaily Evidence Check on a Small, Open Trial Stage
The scale of the survival gap is striking. The scale of the trial is not, and readers deserve both facts in the same breath.
Eighty-seven patients is a small randomized comparison for a survival claim in lung cancer. The companies called the result statistically significant, but the reported p-value was nominal, meaning it was not adjusted for the statistical multiplicity that a confirmatory analysis requires. The trial is open-label, so patients and doctors knew which treatment was given. And this was the non-pivotal stage. The portion of PRESERVE-003 designed to support approval is still enrolling at more than 160 sites worldwide, with overall survival as its primary endpoint.
Gotistobart is not approved by the FDA or any other regulator. Nothing about Monday's announcement changes treatment guidelines, insurance coverage, or what an oncologist can offer a patient this week. The investigator quoted by the companies framed the result conditionally, saying the findings could transform the standard of care in this setting "if confirmed in the pivotal portion of the Phase 3 trial."
Both firms have a direct financial interest in the outcome, which is a normal feature of industry-sponsored trials and a reason independent confirmation matters.
Practical Steps for Patients and Caregivers Right Now
Nobody should change a treatment plan based on a conference presentation. Patients currently on docetaxel or considering it should keep that conversation with their own oncology team, since the comparison drug here is still the standard.
For families who want to pursue the drug, the realistic route is a clinical trial. The pivotal stage of PRESERVE-003 is active at a large number of centers, and asking an oncologist or a cancer center's trial navigator about eligibility is a reasonable next step. Squamous histology, prior progression on a PD-(L)1 inhibitor, and prior platinum chemotherapy were the entry conditions in the reported stage.
Two practical questions are worth raising at that appointment: whether tumor genomic testing is complete, since results can point toward other approved options, and whether travel to a trial site is financially and physically feasible. Trial participation often covers study drug costs but not travel or lost work time, and hospital financial navigators can help map that out.
Anyone with worsening breathlessness, chest pain, coughing up blood, or rapid weight loss needs prompt medical evaluation regardless of where they are in treatment. Those symptoms are about the cancer, not the study.
The next meaningful milestone is the readout from the pivotal stage, which the companies have not dated publicly. MedicalDaily will track that result and any FDA submission that follows. Until then, the honest summary is that a small trial stage produced an unusually large survival signal that has not yet been confirmed, in a group of patients who have waited a long time for anything new.
Key Questions Answered
What was announced? BioNTech and OncoC4 released the first median overall survival data from stage 1 of the PRESERVE-003 Phase 3 trial, showing 18.5 months with gotistobart versus 10.0 months with docetaxel chemotherapy.
Which patients were studied? Eighty-seven adults with metastatic squamous non-small cell lung cancer whose disease had progressed after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy, treated in the second line or later.
Can a patient get this drug now? No. Gotistobart is investigational and has not been approved by the FDA or any other regulator. Access is only through clinical trial enrollment.
How solid is the evidence? It is encouraging but preliminary. The sample was small, the trial stage was non-pivotal and open-label, and the reported p-value was nominal rather than confirmatory.
Were side effects worse than chemotherapy? Not by this measure. Grade 3 or higher treatment-related side effects occurred in 44.4% of gotistobart patients and 48.8% of docetaxel patients. Immune-related side effects remain a known concern with CTLA-4 drugs.
What should patients do with this information? Discuss trial eligibility with an oncologist and continue current treatment as prescribed. No one should stop or delay an existing regimen based on these results.
When will there be more information? The pivotal second stage is ongoing at more than 160 sites globally. Its overall survival results will determine whether the drug advances toward regulatory review.
